US · Healthcare · Medical Instruments & Supplies
EPS came in at 0.26 against a street estimate of 0.05 — a beat of 420.0%.
Analysts rate STAAR Surgical Company a buy (4 buy, 6 hold, 1 sell out of 11) with an average price target of $27.67.
| Fund | Stake |
|---|---|
| BROADWOOD CAPITAL Inc | 32.16% |
| BlackRock Inc | 13.42% |
| Madison Avenue Partners, LP | 8.33% |
| Yunqi Capital Ltd | 6.50% |
| Point72 Asset Management, L.P. | 4.86% |
| The Goldman Sachs Group Inc | 4.29% |
| Vanguard Portfolio Management, LLC | 3.95% |
| State Street Corp | 3.53% |
| Document | Date |
|---|---|
| Quarterly report · Q3 FY2027 HEADLINE NUMBERS • Third-quarter net sales were $83,411, down from $94,732 in the comparable 2025 quarter. • Nine-month net sales were $270,468, up | 2026-11-04 |
| Results announced · Q4 FY2027 HEADLINE NUMBERS • Third-quarter 2026 net sales were $83.4 million, down 12% year over year. Excluding $25.9 million of previously deferred China sal | 2026-11-04 |
| Board / officer change · Q3 FY2027 STAAR SURGICAL COMPANY - 8-K SUMMARY BUSINESS & SEGMENT HIGHLIGHTS • STAAR Surgical Company appointed David Bailey as Chief Commercial Officer, effe | 2026-09-10 |
| Quarterly report · Q2 FY2027 STAAR SURGICAL COMPANY – 10-Q SUMMARY Quarter Ended July 3, 2026 --- HEADLINE NUMBERS • Net sales (6 months): $187,057 thousand vs. $86,909 thousan | 2026-08-12 |
| Results announced · Q3 FY2027 STAAR SURGICAL Q2 2026 RESULTS SUMMARY HEADLINE NUMBERS • Net sales: $93.5 million, up 111% year-over-year (Q2 2025: $44.3 million) • Net income: $8 | 2026-08-12 |
| Board / officer change · Q3 FY2027 STAAR SURGICAL COMPANY – 8-K SUMMARY HEADLINE NUMBERS • Warren Foust appointed President and CEO effective August 4, 2026, and added to Board of Dir | 2026-08-06 |
| Board / officer change · Q2 FY2027 STAAR SURGICAL COMPANY – 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 18, 2026 • 49,788,295 shares outstanding as of April 20 | 2026-06-22 |
| Board / officer change · Q2 FY2027 STAAR SURGICAL COMPANY (STAA) – 8-K SUMMARY HEADLINE NUMBERS • Deborah Andrews (Interim Co-CEO and CFO) base salary increased from $512,000 to $575, | 2026-06-09 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorized a $50 million share repurchase program STAAR Surgical reported third-quarter 2026 net sales of $83.4 million, down 12% year over year, and net income of $5.6 million, or $0.11 per diluted share. Adjusted EBITDA was $14.4 million, | 2026-11-04 |
| Special stockholder meeting held regarding merger agreement with Alcon STAAR Surgical Company held a special stockholder meeting on January 6, 2026, to vote on a merger agreement with Alcon Research, LLC. The merger was originally signed on August 4, 2025, and | 2026-01-06 |
| Termination of material merger agreement with Alcon STAAR Surgical's planned merger with Alcon Research has been terminated as of January 6, 2026. The company held a shareholder vote on the merger agreement, but it was decisively rejected. On | 2026-01-06 |
| Amendment to merger agreement with Alcon entered into STAAR Surgical Company announced it has agreed to increase the merger consideration from Alcon Research, LLC from $28.00 per share to $30.75 per share in cash. This represents an approximate | 2025-12-09 |
| Go-shop process expires; merger with Alcon proceeding as planned STAAR Surgical announced on December 8, 2025, that its 'go-shop' process has concluded. This process allowed the company to solicit alternative acquisition proposals after entering into a me | 2025-12-08 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for STAAR Surgical Company — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.